Your browser doesn't support javascript.
loading
Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies.
Tuyishime, Marina; Garrido, Carolina; Jha, Shalini; Moeser, Matt; Mielke, Dieter; LaBranche, Celia; Montefiori, David; Haynes, Barton F; Joseph, Sarah; Margolis, David M; Ferrari, Guido.
  • Tuyishime M; Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
  • Garrido C; UNC HIV Cure Center and.
  • Jha S; Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
  • Moeser M; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Mielke D; Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
  • LaBranche C; Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
  • Montefiori D; Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
  • Haynes BF; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA.
  • Joseph S; Department of Medicine and.
  • Margolis DM; Department of Immunology, Duke University Medical Center, Durham, North Carolina, USA.
  • Ferrari G; UNC HIV Cure Center and.
J Clin Invest ; 130(10): 5157-5170, 2020 10 01.
Article en En | MEDLINE | ID: mdl-32584790
ABSTRACT
The correlation of HIV-specific antibody-dependent cellular cytotoxicity (ADCC) responses with protection from and delayed progression of HIV-1 infection provides a rationale to leverage ADCC-mediating antibodies for treatment purposes. We evaluated ADCC mediated by different combinations of 2 to 6 neutralizing and non-neutralizing anti-HIV-1 Envelope (Env) mAbs, using concentrations ≤ 1 µg/mL, to identify combinations effective at targeting latent reservoir HIV-1 viruses from 10 individuals. We found that within 2 hours, combinations of 3 mAbs mediated more than 30% killing of HIV-infected primary CD4+ T cells in the presence of autologous NK cells, with the combination of A32 (C1C2), DH511.2K3 (MPER), and PGT121 (V3) mAbs being the most effective. Increasing the incubation of target and effector cells in the presence of mAb combinations from 2 to 24 hours resulted in increased specific killing of infected cells, even with neutralization-resistant viruses. The same combination eliminated reactivated latently HIV-1-infected cells in an ex vivo quantitative viral outgrowth assay. Therefore, administration of a combination of 3 mAbs should be considered in planning in vivo studies seeking to eliminate persistently HIV-1-infected cells.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Anticuerpos Anti-VIH / Infecciones por VIH / VIH-1 / Anticuerpos Neutralizantes Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Año: 2020 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Anticuerpos Anti-VIH / Infecciones por VIH / VIH-1 / Anticuerpos Neutralizantes Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Año: 2020 Tipo del documento: Article